Melanoma patients and Quality of Life after active treatment
- Conditions
- Melanoma (stage III/IV)
- Registration Number
- NL-OMON26948
- Lead Sponsor
- o sponsors, the study is investigator initiated
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
In order to participate in this study, patients have to be:
-At least 18 years of age
-Actively treated for melanoma by use of immunotherapy, surgery or a combination.
-Willing to fill in one questionnaire and perform one online cognition test.
Exclusion Criteria
A potential subject who meets any of the following criteria will be excluded from participation in this study:
-Insufficient understanding of the Dutch or English language
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome will be assessed by use of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30). The EORTC QLQ-C30 is a self-reported questionnaire, specifically developed for patients with cancer who are receiving cancer treatment. The EORTC-QLQ- C30 is widely accepted and validated in clinical studies.
- Secondary Outcome Measures
Name Time Method - Melanoma (surgery) specific symptoms (Functional Assessment of Cancer Therapy- Melanoma; FACT-M)<br>- Sociodemographic data<br>- Anxiety and depression (Hospital Anxiety and Depression Scale; HADS)<br>- Worry about cancer (Cancer Worry Scale; CWS)<br>- Immunotherapy-related discomforts<br>- Sexual health (EORTC sexuality questionnaire)<br>- Work ability<br>- Quality-adjusted life years (QUALYs) by means of the 5 level EuroQoL-5D<br>- Cognitive status (Amsterdam Cognition Scan)